论文部分内容阅读
目的:探讨芪芍胶囊联合厄贝沙坦治疗糖尿病肾病(DKD)患者的疗效。方法:选取2014年1月至2015年4月期间河北省中医院收治的84例DKD患者为研究对象,并随机分为观察组和对照组,两组各42例。对照组给予厄贝沙坦治疗,150 mg qd,观察组在对照组治疗的基础上加用芪芍胶囊,5粒tid。比较两组治疗前后的糖代谢指标和肾功能指标,并比较两组患者的疗效。结果:治疗后观察组的空腹血糖(FPG),糖化血红蛋白(Hb A1c)均显著低于对照组(P<0.05),治疗后观察组的血肌酐(SCr),尿蛋白排泄率(UAER),24 h尿蛋白(24 h UP),尿微量白蛋白(m ALB),尿微量白蛋白与肌酐比(m ALB/UCr),血尿素氮(BUN)分别为(135.7±18.9)μmol·L-1,(155.3±28.1)mg·(24 h)-1,(1.53±0.44)g,(39.7±12.9)μg·L-1,(15.5±3.9)mg·g-1,(6.59±0.87)mmol·L-1,均显著低于对照组的(163.6±18.0)μmol·L-1,(170.6±32.3)mg·(24 h)-1,(1.79±0.52)g,(47.4±14.4)μg·L-1,(17.7±3.8)mg·g-1,(7.06±0.93)mmol·L-1(P<0.05)。观察组的临床疗效明显优于对照组(P<0.05)。结论:与单用厄贝沙坦相比,芪芍胶囊联合厄贝沙坦治疗能更加显著地改善DKD患者的肾功能,延缓其进展,疗效显著,充分显示了中西医治疗的独特优势,值得临床推广应用。
Objective: To investigate the therapeutic effect of Qishao capsule combined with irbesartan on patients with diabetic nephropathy (DKD). Methods: From January 2014 to April 2015, 84 cases of DKD patients admitted to Hebei Provincial Hospital of Traditional Chinese Medicine were selected as study subjects and randomly divided into observation group and control group, with 42 cases in each group. The control group received irbesartan treatment, 150 mg qd, the observation group in the control group based on the treatment with qishao capsule, 5 tid. The levels of glucose metabolism and renal function were compared between the two groups before and after treatment, and the curative effect of the two groups was compared. Results: After treatment, the levels of fasting blood glucose (FPG) and Hb A1c in the observation group were significantly lower than those in the control group (P <0.05). After treatment, the levels of serum creatinine (SCr), urinary protein excretion (UAER) 24 h urine protein, m ALB, m ALB / UCr and BUN were (135.7 ± 18.9) μmol·L- 1, (155.3 ± 28.1) mg · (24 h) -1, (1.53 ± 0.44) g, (39.7 ± 12.9) μg · L -1, (15.5 ± 3.9) mg · g -1, (6.59 ± 0.87) (170.6 ± 32.3) mg · (24 h) -1, (1.79 ± 0.52) g and (47.4 ± 14.4) mmol · L-1 in the control group were significantly lower than those in the control group (163.6 ± 18.0) μmol·L- μg · L-1, (17.7 ± 3.8) mg · g-1, (7.06 ± 0.93) mmol·L-1 (P <0.05). The clinical efficacy of the observation group was significantly better than that of the control group (P <0.05). CONCLUSIONS: Compared with irbesartan alone, the combination of Qishao capsule and irbesartan can significantly improve the renal function, delay the progression of DKD patients and has a significant curative effect. It fully demonstrates the unique advantages of TCM and WM and is worthy Clinical application.